Altogether, we corroborate that ELAVL1 expression and SUMO dynamics are decompensated in human liver cancer tumors, which led us to describe that HuR is SUMOylated in HCC mouse and human cell line models and, more importantly, in patients. This evidence concerns the gene ELAVL1 and hepatocellular carcinoma.